Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

Background: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS). The interleukin-6 receptor inhibitor tocilizumab is used for the treatment of chimeri...

Full description

Bibliographic Details
Main Authors: Antonio Mastroianni, Sonia Greco, Giovanni Apuzzo, Salvatore De Santis, Carmela Oriolo, Alfredo Zanolini, Luciana Chidichimo, Valeria Vangeli
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:EClinicalMedicine
Subjects:
Cytokine release syndrome
Coronavirus disease 2019
Tocilizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020301541

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020301541

Similar Items